Prior studies show efficacy of statins, BET/CDK7 inhibitors, and SOAT1 blockade (e.g., avasimibe) in osteosarcoma or related cancer models, with SREBP-axis inhibitors (e.g., fatostatin) providing complementary upstream control. Here, CDK7 is linked to cancer.